- Trial phase
- Preclinical
- Time to market
- SPY007 is in preclinical development with no disclosed IND filing. Assuming successful preclinical work, Phase 1 initiation is likely at least 12-18 months away. Commercialization, if successful, would be several years out (likely 2030 or later).
- Why 2/10
- SPY007 is a preclinical-stage asset with no IND filed and no clinical trial initiated. The next hard catalyst for the SPY772 program (which includes SPY007) is the SKYLIGHT Phase 2 topline Week 16 HiSCR75 data, expected late 2027 or early 2028, more than 12 months away. SPY007 is a minor part of Spyre's broader pipeline, which includes multiple Phase 2 programs (SPY001, SPY002, SPY003, SPY072) that are more advanced and more central to the company's near-term value.
SPY007 is too early-stage to drive near-term stock movement. The next relevant catalyst for the SPY772 program (which includes SPY007) is the SKYLIGHT Phase 2 topline Week 16 HiSCR75 data, expected late 2027 or early 2028. Watch for any IND filing or Phase 1 initiation for SPY007 as a standalone molecule, which would signal advancement of this preclinical asset.
Price Chart
Executive Summary
SPY007 is a preclinical-stage, long-acting anti-IL-17A/F antibody being developed by Spyre Therapeutics (NASDAQ: SYRE) as part of the SPY772 combination program with SPY072 (anti-TL1A) for hidradenitis suppurativa (HS). SPY007 itself has not entered clinical trials and has no disclosed IND filing. The SPY772 program's SKYLIGHT Phase 2 trial, initiated in August 2026, is currently testing the already-approved anti-IL-17A/F drug bimekizumab (not SPY007) in combination with SPY072, with topline data expected late 2027 or early 2028. Spyre has a deep pipeline with multiple Phase 2 programs and a strong cash position of approximately $1.47 billion pro forma, but SPY007 is an early-stage, minor component of the overall story with no near-term binary catalyst.
How It Works
SPY007 is a long-acting monoclonal antibody designed to block two related inflammatory proteins called IL-17A and IL-17F. These are signaling molecules (cytokines) that drive inflammation in autoimmune diseases. By neutralizing both IL-17A and IL-17F, the drug aims to reduce the inflammatory response that underlies conditions like hidradenitis suppurativa (a chronic skin condition causing painful lesions). Spyre's version is engineered on an extended-half-life platform, meaning it could potentially be injected less frequently than existing drugs in this class.
Trial Status
SPY007 is in preclinical development. It has not entered human clinical trials. The related SPY772 program (SPY007 + SPY072 combination) launched in August 2026 with the SKYLIGHT Phase 2 trial, but that trial uses bimekizumab (an approved anti-IL-17A/F drug) rather than SPY007 as the IL-17A/F inhibitor. The SKYLIGHT trial is a randomized, placebo-controlled proof-of-concept study in approximately 150 patients with hidradenitis suppurativa, with topline Week 16 HiSCR75 data expected late 2027 or early 2028.
The Two-Sided Case
Upcoming Catalysts
- SKYLIGHT Phase 2 topline Week 16 HiSCR75 data (late 2027 or early 2028) - will inform whether the SPY772 combination approach is viable
- Potential IND filing and Phase 1 initiation for SPY007 as a standalone molecule (no date disclosed)
- Phase 2 readouts for more advanced pipeline assets (SPY001, SPY002, SPY003, SPY072) in 2026-2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Spyre Therapeutics, Inc. PRESS-RELEASE SYRE ·Originating report